December 11th 2025, 10:00pm
I struggle to understand why people support policies and leaders that make healthcare less affordable and accessible for everyone.
December 11th 2025, 9:00pm
CURE spoke with Dr. Dickran Kazandjian about why MRD matters for patients with multiple myeloma.
December 11th 2025, 6:46pm
The 60-month local regional recurrence-free rate was 93.2% in the MRI arm versus 95.7% in the no MRI arm, researchers reported.
December 11th 2025, 5:51pm
Enhertu and Perjeta led to better quality-of-life and less side effects than standard-of-care among patients with HER2+ advanced or metastatic breast.
December 11th 2025, 5:43pm
Adding radiation before surgery with Keytruda increased immune cells in tumors and led to encouraging responses in people with early-stage breast cancer.
December 11th 2025, 4:06pm
Tecentriq numerically increased the rates of chemotherapy-induced ovarian failure compared with chemotherapy alone for patients with triple-negative breast cancer.
December 11th 2025, 3:36pm
Verzenio showed meaningful improvement for some patients with HR-positive, HER2-negative breast cancer after prior CDK4/6 treatment.
December 11th 2025, 2:00pm
Tukysa added to Herceptin and Perjeta improved progression-free survival versus placebo in HER2-positive metastatic breast cancer after initial therapy.
December 10th 2025, 10:00pm
Dan, diagnosed with stage 4 pancreatic cancer, shares his journey to remission and insights on clinical trials and patient advocacy.
December 10th 2025, 9:48pm
Nuvisertib plus momelotinib is safe and generated improvements in symptom burden, spleen volume, and anemia outcomes in relapsed/refractory myelofibrosis.
Knowledge Isn’t Enough When Action Costs Too Much
What Does Minimal Residual Disease Mean?
Preoperative Breast MRI Did Not Improve Outcomes in Early-Stage Breast Cancer
Enhertu/Perjeta Combo Enhances Quality of in HER2+ Advanced Breast Cancer